![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Reva Receives CE Mark for Fantom Encore Bioresorbable Scaffold
Reva Receives CE Mark for Fantom Encore Bioresorbable Scaffold
![](https://www.fdanews.com/ext/resources/test/Device_Images6/RevaMedical_Logo.gif?t=1519687103&width=430)
February 26, 2018
Reva received a CE mark and reported the first implant of the Fantom Encore bioresorbable scaffold.
Bioresorbable scaffolds were developed as an alternative to metal drug-eluting stents for the treatment of coronary artery disease. The Fantom Encore offers a thin profile without compromising strength or X-ray visibility, using improved polymer processing and manufacturing techniques.
REVA expects to launch the entire Fantom Encore product line later this year.
Upcoming Events
-
21Oct